On January 31, 2024, Aclaris Therapeutics, Inc. terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.215 USD | +1.25% | -0.41% | +15.71% |
Mar. 19 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
Feb. 27 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.71% | 85.52M | |
+2.59% | 42.75B | |
+47.70% | 41.61B | |
+12.21% | 41.34B | |
-8.83% | 26.59B | |
+7.92% | 25.49B | |
-22.51% | 18.12B | |
+31.23% | 12.24B | |
-1.47% | 11.76B | |
+8.57% | 11B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer